Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails

Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond.

But many patients still do not respond to therapies such as Merck & Co’s anti PD-1 therapy Keytruda (pembrolizumab), or go on to develop progressive disease, and pharma companies are looking for new second-line therapies.